Clinical Trials

We are currently participating in the following clinical trials:
(Click on trials for additional information from the National Institutes of Health.)


DAYBREAK Study: Study of LY3314814 in Mild Alzheimer's Dementia
Multicenter, randomized, parallel-group, 78-week double blind, placebo-controlled, study of LY3314814 in patients with mild Alzheimer's dementia, followed by a 78-week delayed-start period. LY3314814 is a brain-permeable inhibitor being developed for the modification of the clinical course of Alzheimer's disease by slowing disease progression in patients diagnosed with early Alzheimer's dementia.
Sponsor: Eli Lilly & Co
Enrollment period: Open

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease
Multicenter, randomized, double-blind, parallel group, 26-weeks, placebo-controlled study of SUVN-502 in patients with moderate Alzheimer's disease currently treated with Donepezil and Memantine. SUVN-502 is proposed as a novel, highly selective and orally active antagonist at 5-HT6 serotonin receptor that is intended for the treatment of cognitive disorders associated with Alzheimer's disease.
Sponsor: Suven Life Sciences
Enrollment period: Open

Engage Study: A Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease with administration of Aducanumab IV monthly for 2 years, followed with open extension study.
Sponsor: Biogen
Enrollment period: Open

STEADFAST Study: Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Study to evaluate the efficacy and safety of Azeliragon in patients with mild Alzheimer's disease currently on Acetylcholinesterase Inhibitors. Patients will receive either Azeliragon or placebo for approximately 18 months, followed with 2 years of open-label extension.
Sponsor: vTv Therapeutics
Enrollment period: Follow up phase

SERENE Study: Treatment of Agitation and Aggression in Alzheimer's Disease
Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer;s disease.
Sponsor: ACADIA Pharmaceuticals
Enrollment period: Open

RaMP Study: Alzheimer Registry for those Interested in Future Study
A registry that will be used to identify patients who have suspected Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for Alzheimer's Disease drug research trials in the future.
Sponsor: Eli Lilly & Co
Enrollment period: Open

Mission AD1: A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
Multicenter, double-blind, placebo-controlled, parallel group, in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of Elenbecestat.
Sponsor: Eisai Co
Enrollment period: Open

Trial of Verubecestat in Participants With Prodromal Alzheimer's Disease (APECS)
Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD), for 2 year, followed with 5 years of open label extension.
Sponsor: Merck Sharp & Dohme Corp
Enrollment period: Follow up phase


Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
To evaluate the efficacy, safety and tolerability of two oral doses of UBROGEPANT, (CGRP compound) vs. a placebo for the acute treatment of a single migraine attack. The 1 year extension study is available for those who complete the initial study.
Sponsor: Allergan
Enrollment period: Open

PROMISE 1 STUDY: A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
To evaluate ALD403 in patients with Frequent Episodic Migraines via IV every three months for one year. ALD403 is a CGRP antagonist for the prophylaxis of migraines. CGRP is thought to play an important role in migraine.
Sponsor: Alder
Enrollment period: Follow up phase


Twelve Month Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena).
Sponsor: Acorda Therapeutics
Enrollment period: Follow up phase


PASSAGE STUDY: Study in Patients With Multiple Sclerosis Treated with Fingolimod
Study in patients with relapsing forms of MS, either newly treated with Fingolimod or receiving another disease-modifying therapy, to further explore the incidence of selected safety related outcomes and to further monitor the overall safety profile of Fingolimod under conditions of routine medical practice.
Sponsor: Novartis Pharmaceuticals
Enrollment period: Open

381 E. Imperial Highway
Fullerton, CA 92835

Ph (714) 879-7200
Fax (714) 879-3010

Why participate in a clinical trial?

Privacy Policy / 2017 © All Rights Reserved